Botulinum neurotoxin injection for the treatment of epiphora in nasolacrimal duct obstruction.

Abstract

PURPOSE:

Retrospective long-term study to evaluate the efficacy of botulinum neurotoxin A (BoNT/A) therapy for epiphora due to non-surgical nasolacrimal duct obstruction.

INTRODUCTION:

BoNT/A has been used successfully since 2000 in axillary hyperhidrosis to reduce secretory disorders. Some isolated cases of hyperlacrimation or crocodile tear syndrome have been treated on this basis. We used BoNT/A to decrease lacrimal secretion in cases of epiphora.

METHODS:

We reviewed the qualitative and quantitative degree of improvement of epiphora after botulinum neurotoxin injections in the palpebral lobe of the lacrimal gland, carried out in an ophthalmic centre between 2009 and 2016. Epiphora was graded using a questionnaire, Munk scores and Schirmer tests before and after injections. Severity of side effects was recorded.

RESULTS:

Twenty-seven palpebral lacrimal glands of twenty patients with epiphora, mean age 65±13, were treated with BoNT/A (Botox® or Xeomin®) from April 2009 to April 2016. The epiphora was induced by persistent nasolacrimal duct stenosis after surgical treatment. No conventional medical nor surgical treatment was effective at this time. The technique of injection, dilution and dosage were specific. We re-injected 14/27 cases on an as-needed basis, 7/27 cases three times, 3/27 cases four times, and 2/27 cases (same patient both glands) five times. The Schirmer test measured a decrease of lacrimal secretion in 24/27 (89%) lacrimal glands after neurotoxin injection. Side effects were ptosis in 4 cases and transient esotropia in 2 cases. The authors describe the injection techniques, the dosage, the volume and concentration of BoNT/A.

CONCLUSION:

Patients with epiphora can be treated effectively with BoNT/A to reduce lacrimal secretion of the principal lacrimal gland in its palpebral portion. Ninety percent of the patients were very satisfied, with few side effects (ptosis or mild diplopia lasting from 3 days to 3 weeks). More studies are needed to delineate which types of epiphora can be treated with BoNT/A.

• Authors: B Girard, J-M Piaton, P Keller, C Abadie, T H Nguyen
• Journal: Journal francais d'ophtalmologie (J Fr Ophtalmol) Vol. 40 Issue 8 Pg. 661-665 (Oct 2017) ISSN: 1773-0597 [Electronic] France
• PMID: 28847443 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Chemical References

• Botulinum Toxins, Type A
• incobotulinumtoxinA

Topics

• Aged
• Blepharoptosis (drug therapy, etiology)
• Botulinum Toxins, Type A (administration & dosage, adverse effects)
• Female
• Humans
• Injections, Intraocular (adverse effects)
• Lacrimal Apparatus Diseases (complications, drug therapy)
• Lacrimal Duct Obstruction (complications, drug therapy)
• Male
• Middle Aged
• Nasolacrimal Duct (drug effects, pathology)
• Retrospective Studies
• Treatment Outcome